The FDA has accepted a supplemental new drug application for Dextenza for the treatment of ocular itching associated with allergic conjunctivitis, according to a press release from Ocular Therapeutix.
“The use of topical steroids is an important part of the clinical armamentarium in the treatment of a patient with allergic conjunctivitis, and if approved for this new proposed use, Dextenza could provide an office-based, physician-administered, preservative-free method of steroid delivery that benefits patients with ocular itching associated with allergic conjunctivitis,” Patricia
Uncategorized